English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

. The triple therapy which consists of one of the protease   inhibitor plus pegylated interferon and ribavirin (P/R) is the standard of   care for the treatment of chronic hepatitis C virus (HCV) genotype 1(G1)   infection both in treatment-naпve and experienced patients. Objective. The   aim of this study was to analyze the efficacy and tolerability of this regime   in hospital practice in Serbia. Methods. From July 2012 to October 2012, 20   previously treated patients with advanced fibrosis and HCV G1 infection were   included in the triple antiviral regimen in six referral centers in Serbia.   All patients were treated with response guide therapy (RGT) regime according   to the boceprevir treatment protocol. During the 4-week lead-in period all   patients received peginterferon plus ribavirin. After the lead-in period   boceprevir was added in the dosage of 800 mg three times a day orally. The   subsequent treatment varied according to virologic response and fibrosis.   During the therapy HCV RNA level was measured at week 4, 8, 12, 24 of the   treatment for the assessment of virologic response profile. All patients who   completed therapy were assessed at the end of the treatment and at the end of   an additional 24-week treatment-free period for a sustained virologic   response (SVR). Results. The total of 20 patients with advanced fibrosis was   treated. Among patients with an undetectable HCV RNA level at week 8 the rate   of SVR was 100%. No patient with decrease in the HCV RNA level <1 log 10   IU/ml at treatment week 4 achieved SVR. The overall rate of SVR was 55%. The   safety profile of the treatment regimen was good. Anemia was reported in 25%   of patients. There was no life-threatening treatment adverse event.   Conclusion. Boceprevir in combination with P/R achieved fairly good SVR rates   in patients that were “most difficult to treat” who failed on dual therapy   and was effective among patients with cirrhosis

Boceprevir in genotype 1 chronic hepatitis C: First experiences in Serbia